713 results about "Biological effect" patented technology

An apparatus and method for treating subcutaneous tissues using acoustic waves in the range of low acoustic pressure ultrasound waves is disclosed. The method includes injections of enhancing agents, wherein disruption of subcutaneous tissues and subcutaneous cavitational bioeffects are produced by ultrasound waves having a power that will not produce tissue cavitation in the absence of the enhancing agents. The apparatus and method of use is useful for treatment of subcutaneous abnormalities including cellulite, lipomas, and tumors.

The invention relates nucleic acids and their encoded polypeptides, whose expression is modulated in cancer or tumor cells. The invention further relates to methods useful for treating or modulating cancer or tumors in mammals in need of such biological effect. This includes the diagnosis and treatment of oncological disorders. Additionally, the present invention further relates to the use of antibodies against the polypeptides of the present invention as diagnostic probes or as therapeutic agents as well as the use of polynucleotide sequences encoding the polypeptides of the present invention as diagnostic probes or therapeutic agents for the treatment of a broad range of pathological states.

A lighting system for creating a biological effect induced by light. The biological effect is a different effect than vision. The lighting system comprises a light source (1) to generate light with a varying spectrum, and a driver (2) to drive the light source (1) to successively in time: (i) generate a first spectrum (S1) during a first period in time (T1), (ii) change the first spectrum (S1) into a second spectrum (S2) during a second period in time (T2), wherein the second spectrum (S2) has the biological effect, and (iii) maintain the second spectrum (S2) during a third period in time (T3). The duration of the second period in time (T2) is selected in a range from 5 seconds to 30 minutes. The first spectrum (S1) may not have the biological effect or may have the biological effect to a smaller extent than the second spectrum (S2).

The present invention relates to nucleic acids and polypeptides encoded thereby, whose expression is modulated in brain microvascular endothelial cells undergoing early dynamic inflammation-induced changes in blood-brain barrier functionality. Such polypeptides are referred to as lipopolysaccharide-sensitive (LPSS) polypeptides herein. These nucleic acids and polypeptides may be useful in methods for controlling blood-brain barrier properties in mammals in need of such biological effects. This includes the diagnosis and treatment of disturbances in the blood-brain / retina barrier, brain (including the eye) disorders, as well as peripheral vascular disorders. Additionally, the invention relates to the use of anti-LPSS polypeptide antibodies or ligands as diagnostic probes, as blood-brain barrier targeting agents or as therapeutic agents as well as the use of ligands or modulators of expression, activation or bioactivity of LPSS polypeptides as diagnostic probes, therapeutic agents or drug delivery enhancers.

The novel germ-line transformation systems disclosed in this patent application allow the physical deletion of transposon DNA following the transformation process, and the targeting of transgene integrations into predefined target sites. In this way, transposase-mediated mobilization of genes-of-interest is excluded mechanistically and random genomic integrations eliminated. In contrast to conventional germ-line transformation technology, our systems provide enhanced stability to the transgene insertion. Furthermore, DNA sequences required for the transgene modification (e.g. transformation marker genes, transposase or recombinase target sites), are largely removed from the genome after the final transgene insertion, thereby eliminating the possibility for instability generated by these processes. The RMCE technology, which is disclosed in this patent application for invertebrate organisms (exemplified in Drosophila melanogaster) represents an extremely versatile tool with application potential far beyond the goal of transgene immobilization. RMCE makes possible the targeted integration of DNA cassettes into a specific genomic loci that are pre-defined by the integration of the RMCE acceptor plasmid. The loci can be characterized prior to a targeting experiment allowing optimal integration sites to be pre-selected for specific applications, and allowing selection of host strains with optimal fitness. In addition, multiple cassette exchange reactions can be performed in a repetitive way where an acceptor cassette can be repetitively exchanged by multiple donor cassettes. In this way several different transgenes can be placed precisely at the same genomic locus, allowing, for the first time, the ability to eliminate genomic positional effects and to comparatively study the biological effects of different transgenes.

Compositions, kits and methods are provided for promoting general health or for prevention or treatment of diseases by using novel recombinant fusion proteins of human serum albumin (HSA) and bioactive molecules. The bioactive molecules may be a protein or peptide having a biological function in vitro or in vivo, and preferably, having a therapeutic activity when administered to a human. By fusing the bioactive molecule to HSA, stability of the bioactive molecule in vivo can be improved and the therapeutic index increased due to reduced toxicity and longer-lasting therapeutic effects in vivo. In addition, manufacturing processes are provided for efficient, cost-effective production of these recombinant proteins in yeast.

A magnetic field generator includes a power source and a coil connected to the power source to generate a time-varying magnetic field. Energy is applied to the coil so that the coil generates a time-varying magnetic field gradient with a magnitude of at least 1 milliTesla per meter and a rise-time of less than 10 microseconds. One or more of a capacitor, a multi-stage high-voltage switch, and / or a pulse-forming network may assist with the generation of the magnetic field gradient.

Larmor Precession makes specific predictions about bound ion dynamics, based upon specific combinations of AC and DC magnetic fields. Especially significant is the fact that the external magnetic field environment determines the overall qualities of resonances or particular changes in bio-effects. Given a target with a particular gyromagnetic ratio, Larmor Precession makes predictions that are determined solely by a magnetic field environment itself. An embodiment according to the present invention comprises specific combinations of AC and DC magnetic fields configured to produce specific bio-effects. Preferably an embodiment according to the present invention comprises using Larmor Precession to develop Electromagnetic Field environments targeted towards enhancing or diminishing specific biological processes, including tumor growth, bone and tissue repair, and biological processes and using Larmor Precession to generate magnetic field conditions that take advantage of specific behaviors, including resonances conditions.

Methods for improving the biological and pharmaceutical properties of bispecific binding agents are described herein where the bispecific binding agent are able to target cells by a high affinity binding domain to a first cell surface marker that does not induce a significant biological effect and a low affinity binding domain that binds specifically to a second cell surface marker, causing a significant and desired biological effect. Compositions of such bispecific binding agents, uses for them, and kits containing them are also provided.

A tunable LED lamp for producing biologically-adjusted light having a housing, a power circuit, a driver circuit disposed within the housing and electrically coupled with the power circuit, and a plurality of LED dies electrically coupled to and driven by the driver circuit. The driver circuit may drive the plurality of LED dies to emit a phase-shift light having a first spectral power distribution, a general illuminating light having a second spectral power distribution, and a pre-sleep light having a third spectral power distribution. The phase-shift light may be configured to affect a first biological effect in an observer, and the pre-sleep light may be configured to affect a second biological effect in an observer. The LED lamp may include an intermediate base to couple the lamp to an Edison screw base. The LED lamp may be configured to operate responsive to a three-way switch.

A lighting system for creating a biological effect induced by light. The biological effect is a different effect than vision. The lighting system comprises a light source (1) to generate light with a varying spectrum, and a driver (2) to drive the light source (1) to successively in time: (i) generate a first spectrum (S1) during a first period in time (T1), (ii) change the first spectrum (S1) into a second spectrum (S2) during a second period in time (T2), wherein the second spectrum (S2) has the biological effect, and (iii) maintain the second spectrum (S2) during a third period in time (T3). The duration of the second period in time (T2) is selected in a range from 5 seconds to 30 minutes. The first spectrum (S1) may not have the biological effect or may have the biological effect to a smaller extent than the second spectrum (S2).

A light-emitting diode (LED) lamp for producing a biologically-corrected light. In one embodiment, the LED lamp includes a color filter, which modifies the light produced by the lamp's LED chips, to increase spectral opponency and minimize melatonin suppression. In doing so, the lamp minimizes the biological effects that the lamp may have on a user. The LED lamp is appropriately designed to produce such biologically-correct light while still maintaining commercially acceptable color temperature and color rending properties. Methods of manufacturing such a lamp are provided, as well as equivalent lamps and equivalent methods of manufacture.

The present invention relates to linear expression elements (LEEs) and circular expression elements (CEEs), which are useful in a variety of molecular biology protocols. Specifically, the invention relates to the use of LEEs and CEEs to screen for gene function, biological effects of gene function, antigens, and promoter function. The invention also provides methods of producing proteins, antibodies, antigens, and vaccines. Also, the invention relates to methods of making LEEs and CEEs, and LEEs and CEEs produced by such methods.